As the CEO of Orange Grove Bio, my passion lies in pushing forward groundbreaking therapies for cancer, autoimmune, and inflammatory diseases. I lead a team of venture partners who are experts in evaluating pre-clinical assets and overseeing companies focused on early-stage pharmaceutical development. Together, we're all about turning promising discoveries into real treatment options for patients.At Orange Grove Bio, we're executing an investment strategy focused on forming partnerships with research institutions and universities often overlooked by coastal-based venture capital firms. By collaborating with a network of co-investors, strategic partners, and world-class experts, Orange Grove Bio is optimizing the technology licensing process and expediting pre-clinical drug development. Our collaborations are strategically targeted in regions such as the Southeast, Midwest, and Mid-Atlantic, fostering additional avenues for innovative research and development beyond traditional biotech hubs. By prioritizing these underexplored regions, we’re tapping into a rich pool of novel therapies and contributing to reshaping the landscape of biopharmaceutical research and development.Before joining Orange Grove Bio, I spent 14 years at GlaxoSmithKline (GSK) in leadership and operational roles, spearheading initiatives to streamline internal processes and accelerating development of novel therapy agents. My background covers everything from drug discovery to project management and strategic planning. I've also led teams that pushed forward multiple clinical candidates during my time at GSK.I obtained my Bachelor of Science in Chemistry and Master of Science in Organic Chemistry from Miami University. Outside the office, I am an avid marathon runner. I have successfully completed several marathons, including the Flying Pig Marathon in Cincinnati and the Abu Dhabi Marathon in the United Arab Emirates.